With the maturity of the domestic biomedicine environment, pharmaceutical companies have shown a general trend of entrusted operation of CDMO business, and CDMO business has broad development potential.
It is learned that Shanghai Zhenge Biotechnology Co., Ltd. (hereinafter referred to as “Zhenge Bio”), A high-tech company engaged in the CDMO business of macromolecular biopharmaceuticals and the development and production of culture medium formulations, has completed a US $ 51 million Series A financing in March 2020. This round of financing was led by LYFE, with IDG Capital, Tongchuang Weiye, KIP Capital (Korea Investment Partners), Junxin Capital, and Guofang’s parent fund co-investing, and Shanghai Jones Day Legal adviser, instant capital involved financial adviser.
It is reported that this round of financing will be mainly used for talent introduction, R & D center expansion, GMP production base construction in Shanghai Port Free Trade Zone Lingang New Area (including large-scale biomedicine pilot and commercial GMP production, culture media GMP commercial production, ADC drug GMP pilot production base, etc.), and the construction of US research and development laboratories.
Zhenge Bio was established in 2017. It is an emerging CDMO technology service provider for macromolecular biopharmaceuticals. Specifically, its core business covers research and development of macromolecular biopharmaceuticals. CDMO services include Process development and engineering scale-up, pilot production, drug IND and BLA declaration, process characterization and verification, project transfer, mammalian cell culture medium development and production, etc .; and equipped with advanced technology research and development equipment, including a complete set of pilots R & D and pilot production equipment (2L to 500L bioreactors, AKTA series purification equipment), and various analytical instruments (LC-MS, HPLC, UPLC, CE, DLS, AUC, etc.) , The intention is to promote the transformation of domestic traditional pharmaceutical companies into biopharmaceutical companies, and accelerate the development and industrialization of macromolecular biopharmaceuticals at home and abroad.
Lab (from WeChat public account of Lingang Blue Bay Future City)
Currently, Zhenge CreatureIn Shanghai Zhangjiang Hi-Tech Park and Zhoupu International Medical Park, the company has 1,500 square meters and 4,500 square meters of biological drug R & D centers and pilot laboratories; in Fengxian District, Shanghai, it has 2000 square meters of biological drug GMP production lines and cell culture medium GMP Commercial production line. Not long ago, Zhenge Biological also started a GMP factory construction project of 10,000 square meters in Shanghai Lingang New Area, and it will continue to build a 60,000 square meters commercial production base of biomedicine. In addition, Zhenge Bio has a 4,000 square foot research and development laboratory in Maryland, USA.
In recent years, with the maturity of the domestic biomedical environment, domestic pharmaceutical companies have set off a wave of innovation; at the same time, investment in pharmaceutical research and development has also increased significantly, and the division of labor in the pharmaceutical industry chain has become increasingly significant. Pharmaceutical companies There is a general trend of entrusting its own R & D and production business to other specialized companies.
Continuous decline in drug prices and rising operating costs are inevitable dual pressures for pharmaceutical companies. CDMO is in the key link between drug research and development and commercial sales. Entrusting CDMO companies to conduct research and development can not only reduce the pressure on enterprises, but also Play a role in promoting the development of enterprises.
In addition, the CDMO industry has also welcomed many positives in recent years. Since 2015, China has accelerated the reform of the pharmaceutical industry, continuously introduced drug policies, and optimized the environment for innovative drugs. With the help of the policy, the number of companies investing in research and development of innovative drugs has increased year by year, and the demand for outsourcing services has also become stronger. On October 23, 2017, the State Food and Drug Administration (CFDA) announced the “Amendment to the Drug Administration Law of the People’s Republic of China (Draft for Solicitation of Drafts)”, which clearly released the holding of drug marketing authorization. The signal of the implementation of the human system to the whole country separated and unbundled the drug marketing authorization from the production authorization, and entrusted CDMO companies with production and research and development models that received policy support, and so on.
Therefore, the biopharmaceutical CDMO industry has become a hot industry sector in China. In recent years, like the industry ’s 乐 威 医疗 , < a href = "https://36kr.com/p/5298690" target = "_ blank"> Opmai have announced high funding.